TY - JOUR
TI - Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients.
AU - Koufos, Nikolaos
AU - Syrios, John
AU - Michailidou, Despina
AU - Xynos, Ioannis D.
AU - Lazaris, Andreas
AU - Kavantzas, Nicolaos
AU - Tomos, Periclis
AU - Kakaris, Stamatis
AU - Kosmas, Christos
AU - Tsavaris, Nikolas
JO - Molecular and Clinical Oncology
PY - 2016
VL - 5
TODO - 4
SP - 440--446
PB - 
SN - 2049-9450, 2049-9469
TODO - 10.3892/mco.2016.966
TODO - chemotherapy, prognostic factors, cytokines, angiogenesis, vascular endothelial growth factor receptors, microvessel density, non-small-cell lung cancer, predictive factors
TODO - The expression of various angiogenic factors was assessed in tumour samples of patients with stage III non-small-cell lung cancer (NSCLC) and further evaluated in  terms of response to induction paclitaxel-ifosfamide-cisplatin chemotherapy. Freshly  isolated lung tumour specimens obtained by bronchoscopy from 70 stage IIIA NSCLC  chemotherapy-naïve patients were sampled and analysed for vascular endothelial  growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3. Microvessel density was  assessed through evaluating the angiogenic markers CD34 and CD105. Immunostaining  scores were calculated by multiplying the percentage of labeled cells by the  intensity of staining for each examined parameter. The overall mean immunostaining  score value from all NSCLC samples was 7.83, 5.56 and 15.86 for VEGFR-1, VEGFR-2 and  VEGFR-3, respectively. The overall mean value of the endothelial antigen CD34 was  16.29, whereas the expression of the CD105 antigen in endothelial cells yielded a  multivariate distribution. Patients who responded to chemotherapy expressed  significantly higher VEGFR-1 and VEGFR-3 mean values compared with non-responders  (P<0.001). No significant difference was noted in VEGFR-2 mean values between these  two groups (P=0.06). The CD34 mean value was significantly higher in responders  (P<0.001), whereas there was no significant difference in CD105 expression between  the two groups (P=0.07). Angiogenic marker expression proved to be a potential  predictive factor of response to chemotherapy in stage III NSCLC. which merits  further investigation.
ER -